ACADIA Pharmaceuticals (ACAD) vs Amylyx Pharmaceuticals (AMLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Amylyx Pharmaceuticals (AMLX) has outperformed ACADIA Pharmaceuticals (ACAD) over the past year, gaining 103.3% versus a loss of 8.8%. Amylyx Pharmaceuticals is the larger company by market cap ($3.44 billion vs $3.39 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACAD | AMLX |
|---|---|---|
| Share price | $19.65 | $27.43 |
| Market cap | $3.39B | $3.44B |
| 1-day change | -0.46% | -2.18% |
| YTD return | -26.43% | +127.07% |
| 1-year return | -8.77% | +103.34% |
| 5-year return | +12.22% | — |
| P/E ratio (TTM) | 8.81 | — |
| Forward P/E | 22.12 | — |
| EPS (TTM) | $2.23 | $-1.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.96 | $41.14 |
| 52-week low | $19.46 | $10.83 |
| Distance from 52-week high | -36.53% | -33.33% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +63.66% | +54.43% |
| Average volume | 1.84M | 2.31M |
| Shares outstanding | 172.31M | 125.51M |
| Employees | 796 | 136 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMLX has outperformed ACAD by 112.1 percentage points over the past year.
About ACADIA Pharmaceuticals
ACAD stock →ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
ACAD vs AMLX FAQ
Which is bigger, ACADIA Pharmaceuticals or Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals (AMLX) is larger, with a market capitalization of $3.44B compared with $3.39B for ACADIA Pharmaceuticals (ACAD).
Which stock has performed better over the past year, ACAD or AMLX?
AMLX returned +103.34% over the past 12 months, compared with -8.77% for ACAD (price return, excluding dividends). Past performance does not predict future results.
Are ACADIA Pharmaceuticals and Amylyx Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.